VVOS vs XRAY vs ALGN vs HSIC vs NVST

For growth investors, Vivos Therapeutics, Inc.

(VVOS) is the stronger pick with 8. 9% revenue growth year-over-year, versus -3. 0% for DENTSPLY SIRONA Inc. (XRAY). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 7x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate Align Technology, Inc. (ALGN) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Henry Schein, Inc.

(HSIC) is the cheapest at 21. 7x versus Envista Holdings Corp at 86. 6x. On forward P/E, DENTSPLY SIRONA Inc. is actually cheaper at 7. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Henry Schein, Inc. wins at 4. 20x versus Envista Holdings Corp's 11. 37x.

Over the past 5 years, Henry Schein, Inc.

(HSIC) delivered a total return of -14. 6%, compared to -99. 6% for Vivos Therapeutics, Inc. (VVOS). Over 10 years, the gap is even starker: ALGN returned +123. 3% versus VVOS's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Vivos Therapeutics, Inc.

(VVOS) is the lower-risk stock at 0. 72β versus DENTSPLY SIRONA Inc. 's 1. 70β — meaning XRAY is approximately 135% more volatile than VVOS relative to the S&P 500. On balance sheet safety, Align Technology, Inc. (ALGN) carries a lower debt/equity ratio of 3% versus 184% for DENTSPLY SIRONA Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Vivos Therapeutics, Inc.

(VVOS) is pulling ahead at 8. 9% versus -3. 0% for DENTSPLY SIRONA Inc. (XRAY). On earnings-per-share growth, the picture is similar: Envista Holdings Corp grew EPS 104. 3% year-over-year, compared to 0. 5% for Align Technology, Inc.. Over a 3-year CAGR, ALGN leads at 2. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Align Technology, Inc.

(ALGN) is the more profitable company, earning 10. 2% net margin versus -74. 1% for Vivos Therapeutics, Inc. — meaning it keeps 10. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALGN leads at 15. 3% versus -74. 3% for VVOS. At the gross margin level — before operating expenses — ALGN leads at 68. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Henry Schein, Inc. (HSIC) is the more undervalued stock at a PEG of 4. 20x versus Envista Holdings Corp's 11. 37x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, DENTSPLY SIRONA Inc. (XRAY) trades at 7. 7x forward P/E versus 17. 0x for Envista Holdings Corp — 9. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for XRAY: 25. 0% to $13. 75.

In this comparison, XRAY (5.

8% yield) pays a dividend. VVOS, ALGN, HSIC, NVST do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Henry Schein, Inc.

(HSIC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 72)). Envista Holdings Corp (NVST) carries a higher beta of 1. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HSIC: +5. 8%, NVST: -13. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VVOS is a small-cap quality compounder stock; XRAY is a small-cap income-oriented stock; ALGN is a mid-cap quality compounder stock; HSIC is a small-cap quality compounder stock; NVST is a small-cap quality compounder stock. XRAY pays a dividend while VVOS, ALGN, HSIC, NVST do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.